Agilent Technologies, Inc. A
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Agilent Technologies, Inc. (A) Free cash flow
Agilent Technologies, Inc.'s free cash flow for fiscal 2025 was $1.2B, down 16.1% from $1.4B in fiscal 2024. Over the twelve months to 31 July 2026 it was $1.3B. Over the past ten years it has ranged from $426.0M (fiscal 2015) to $1.5B (fiscal 2023); the current reading is higher than 73% of that period. Agilent Technologies, Inc. ranks 5th of 52 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.2B | (16.10%) |
| FY2024 | $1.4B | (6.85%) |
| FY2023 | $1.5B | 44.37% |
| FY2022 | $1.0B | (21.28%) |
| FY2021 | $1.3B | 61.52% |
| FY2020 | $803.0M | (7.17%) |
| FY2019 | $865.0M | (5.05%) |
| FY2018 | $911.0M | 27.77% |
| FY2017 | $713.0M | 9.02% |
| FY2016 | $654.0M | 53.52% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jul 2026 | $439.0M | 118.41% |
| Apr 2026 | $201.0M | 14.86% |
| Jan 2026 | $175.0M | (61.28%) |
| Oct 2025 | $452.0M | 74.52% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| IQV IQVIA Holdings Inc. compare | $2.3B |
| DGX Quest Diagnostics Incorporated compare | $1.3B |
| A Agilent Technologies, Inc. | $1.3B |
| IDXX IDEXX Laboratories, Inc. compare | $1.2B |
| ILMN Illumina, Inc. compare | $931.0M |
| MTD Mettler-Toledo International, Inc. compare | $864.0M |
| WAT Waters Corporation compare | $366.6M |
| NTRA Natera, Inc. compare | $84.2M |
| GH Guardant Health, Inc. compare | −$240.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on A
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement